Monitor will probably have the biggest usage numbers if it can become a part of clinical guidelines. It would be aimed at patients who have had clear cystoscopies after a bladder cancer operation. Monitoring for recurrance continues in most cases for a good five years afterwards using cystoscopy at regular intervals with the existing guidelines.
A recurrance resets the cycle so in some cases patients need lifelong monitoring.
So Mal, best not to count your guinea fowl before they hatch, there is a lot to be done to change clinical procedure but this type of clinical validation of efficiency will certainly help the uptake of these tests.
PEB produced an investor update on April 6th last year so with any luck we may have a bit more to mull over this week.
- Forums
- ASX - By Stock
- PEB: Positive Results in Kaiser Permanente User Programme
Monitor will probably have the biggest usage numbers if it can...
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online